|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 9/48 | |
| A61K 31/519 | |||
| A61P 35/00 | |||
| C07D 487/04 | |||
| A61P 35/02 |
| (11) | Patento numeris | 3073999 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 14866302.4 |
| Europos patento paraiškos padavimo data | 2014-11-26 | |
| (97) | Europos patento paraiškos paskelbimo data | 2016-10-05 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2018-05-30 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2014/067586 |
| Data | 2014-11-26 |
| (87) | Numeris | WO 2015/081180 |
| Data | 2015-06-04 |
| (30) | Numeris | Data | Šalis |
| 201310616065 | 2013-11-27 | CN | |
| 201410542609 | 2014-10-14 | CN |
| (72) |
CHEN, Minhua, US
ZHANG, Yanfeng, CN
YANG, Chaohui, CN
ZHANG, Xiaoyu, CN
LU, Fei, CN
GE, Heng, CN
WANG, Peng, US
LI, Pixu, CN
|
| (73) |
Crystal Pharmatech Co., Ltd.,
B4-101 Biobay 218 Xinghu Street Suzhou Industrial Park, Suzhou, Jiangsu 215123,
CN
Suzhou Pengxu Pharmatech Co., Ltd., 3rd Floor, Building E 2358 ChangAn Road Wujiang, Suzhou, Jiangsu 215200, CN |
| (54) | CRYSTALLINE FORM I OF IBRUTINIB |
| CRYSTALLINE FORM I OF IBRUTINIB |